BIIB
Biogen Inc.$182.64+1.97 (+1.09%)Prev Close$180.67·MCap$26.91B·P/E20.36·Vol655.7K·Yield—
▲
Buys (12M)
3
$152.7K
▼
Sells (12M)
18
$8.35M
◆
Net Activity
Net Seller
$8.20M
●
Active Insiders
12
last 12 mo
Over the past 12 months, insider activity at Biogen Inc. (BIIB) has been dominated by selling, with 3 insider purchases totaling $152.7K and 18 insider sales totaling $8.35M. The most recent insider transaction was by Murphy Nicole (officer: Head of Pharm Ops and Tech), who purchased $585.11 worth of shares on Feb 17, 2026. Biogen Inc. operates in the Healthcare sector, within the Drug Manufacturers - General industry, with a market cap of $26.91B.
BIIB Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | Murphy Nicole | officer: Head of Pharm Ops and Tech | Buy | 3 | $195.04 | $585.11 | 19,611 |
| Feb 12, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | Buy | 3 | $195.04 | $585.11 | 0 |
| Feb 6, 2026 | ALEXANDER SUSAN H | EVP Chief Legal Officer | Sell | 3,504 | $201.18 | $704.9K | 0 |
| Feb 6, 2026 | Godbout Sean | Chief Accounting Officer | Sell | 359 | $201.18 | $72.2K | 0 |
| Feb 6, 2026 | Gregory Ginger | EVP, Human Resources | Sell | 2,589 | $201.18 | $520.9K | 0 |
| Feb 6, 2026 | Grogan Jane | Head of Research | Sell | 991 | $201.18 | $199.4K | 0 |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | Sell | 2,038 | $201.18 | $410.0K | 0 |
| Feb 6, 2026 | Keeney Adam | Head of Corporate Development | Sell | 1,583 | $201.18 | $318.5K | 0 |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | Sell | 1,543 | $201.18 | $310.4K | 0 |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | Sell | 3,339 | $201.18 | $671.7K | 0 |
| Feb 6, 2026 | Singhal Priya | Head of Development | Sell | 5,128 | $200.48 | $1.03M | 0 |
| Feb 6, 2026 | Viehbacher Christopher | President and CEO | Sell | 10,980 | $201.18 | $2.21M | 0 |
| Feb 3, 2026 | Singhal Priya | Head of Development | Sell | 1,330 | $179.56 | $238.8K | 0 |
| Dec 3, 2025 | Viehbacher Christopher | President and CEO | Sell | 3,404 | $177.78 | $605.2K | 0 |
| Nov 4, 2025 | Grogan Jane | Head of Research | Sell | 337 | $154.27 | $52.0K | 0 |
| Oct 6, 2025 | Godbout Sean | Chief Accounting Officer | Sell | 8 | $155.25 | $1.2K | 0 |
| Sep 2, 2025 | Singhal Priya | Head of Development | Sell | 1,324 | $132.74 | $175.7K | 0 |
| Jul 16, 2025 | Izzar Rachid | Head of Global Product Strat. | Sell | 2,223 | $135.00 | $300.1K | 0 |
| May 20, 2025 | Singhal Priya | Head of Development | Sell | 3,806 | $126.25 | $480.5K | 0 |
| May 5, 2025 | DORSA CAROLINE | Director | Buy | 1,235 | $122.72 | $151.6K | 0 |
| May 5, 2025 | Keeney Adam | Head of Corporate Development | Sell | 454 | $120.93 | $54.9K | 0 |
| Mar 10, 2025 | SHERWIN STEPHEN A | Director | Sell | 8,760 | $150.02 | $1.31M | 0 |
| Feb 12, 2025 | ALEXANDER SUSAN H | EVP Chief Legal Officer | Sell | 807 | $142.54 | $115.0K | 0 |
| Feb 12, 2025 | Gregory Ginger | EVP, Human Resources | Sell | 634 | $142.54 | $90.4K | 0 |
| Feb 12, 2025 | Izzar Rachid | Head of Global Product Strat. | Sell | 445 | $142.54 | $63.4K | 0 |
| Feb 12, 2025 | Kramer Robin | Chief Accounting Officer | Sell | 245 | $142.54 | $34.9K | 0 |
| Feb 12, 2025 | MCDONNELL MICHAEL R | EVP, Chief Financial Officer | Sell | 1,371 | $142.54 | $195.4K | 0 |
| Feb 12, 2025 | Murphy Nicole | Head of Pharm Ops and Tech | Sell | 670 | $142.54 | $95.5K | 0 |
| Feb 12, 2025 | Singhal Priya | Head of Development | Sell | 357 | $142.54 | $50.9K | 0 |
| Feb 11, 2025 | Izzar Rachid | Head of Global Product Strat. | Sell | 1,165 | $141.35 | $164.7K | 0 |
| Feb 10, 2025 | ALEXANDER SUSAN H | EVP Chief Legal Officer | Sell | 1,234 | $141.35 | $174.4K | 0 |
| Feb 10, 2025 | Gregory Ginger | EVP, Human Resources | Sell | 1,040 | $141.35 | $147.0K | 0 |
| Feb 10, 2025 | Grogan Jane | Head of Research | Sell | 443 | $141.35 | $62.6K | 0 |
| Feb 10, 2025 | Keeney Adam | Head of Corporate Development | Sell | 563 | $141.35 | $79.6K | 0 |
| Feb 10, 2025 | Kramer Robin | Chief Accounting Officer | Sell | 476 | $141.35 | $67.3K | 0 |
| Feb 10, 2025 | MCDONNELL MICHAEL R | EVP, Chief Financial Officer | Sell | 1,502 | $141.35 | $212.3K | 0 |
| Feb 10, 2025 | Murphy Nicole | Head of Pharm Ops and Tech | Sell | 1,223 | $141.35 | $172.9K | 0 |
| Feb 10, 2025 | Singhal Priya | Head of Development | Sell | 681 | $141.35 | $96.3K | 0 |
| Feb 10, 2025 | Viehbacher Christopher | President and CEO | Sell | 3,201 | $141.35 | $452.5K | 0 |
| Jan 31, 2025 | Singhal Priya | Head of Development | Sell | 578 | $143.93 | $83.2K | 0 |
| Dec 6, 2024 | Kramer Robin | Chief Accounting Officer | Sell | 170 | $157.78 | $26.8K | 0 |
| Dec 6, 2024 | Singhal Priya | Head of Development | Sell | 316 | $157.58 | $49.8K | 0 |
| Nov 1, 2024 | Grogan Jane | Head of Research | Sell | 204 | $173.79 | $35.5K | 0 |
| Aug 30, 2024 | Singhal Priya | Head of Development | Sell | 1,238 | $204.57 | $253.3K | 0 |
| May 1, 2024 | Keeney Adam | Head of Corporate Development | Sell | 276 | $216.13 | $59.7K | 0 |
| Apr 2, 2024 | Singhal Priya | Head of Development | Sell | 93 | $213.09 | $19.8K | 0 |
| Apr 1, 2024 | Murphy Nicole | Head of Pharm Ops and Tech | Sell | 117 | $214.83 | $25.1K | 0 |
| Feb 22, 2024 | Singhal Priya | Head of Development | Sell | 262 | $221.23 | $58.0K | 0 |
| Feb 16, 2024 | ALEXANDER SUSAN H | EVP Chief Legal Officer | Sell | 2,437 | $219.08 | $533.9K | 0 |
| Feb 16, 2024 | Gregory Ginger | EVP, Human Resources | Sell | 2,264 | $219.08 | $496.0K | 0 |
Showing 1–50 of 128
1 / 3
BIIB Insider Buying Activity
The following table shows recent insider purchases of Biogen Inc. (BIIB) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | Murphy Nicole | officer: Head of Pharm Ops and Tech | Buy | 3 | $195.04 | $585.11 | 19,611 |
| Feb 12, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | Buy | 3 | $195.04 | $585.11 | 0 |
| May 5, 2025 | DORSA CAROLINE | Director | Buy | 1,235 | $122.72 | $151.6K | 0 |
BIIB Insider Selling Activity
The following table shows recent insider sales of Biogen Inc. (BIIB) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | ALEXANDER SUSAN H | EVP Chief Legal Officer | Sell | 3,504 | $201.18 | $704.9K | 0 |
| Feb 6, 2026 | Godbout Sean | Chief Accounting Officer | Sell | 359 | $201.18 | $72.2K | 0 |
| Feb 6, 2026 | Gregory Ginger | EVP, Human Resources | Sell | 2,589 | $201.18 | $520.9K | 0 |
| Feb 6, 2026 | Grogan Jane | Head of Research | Sell | 991 | $201.18 | $199.4K | 0 |
| Feb 6, 2026 | Izzar Rachid | Head of Global Product Strat. | Sell | 2,038 | $201.18 | $410.0K | 0 |
| Feb 6, 2026 | Keeney Adam | Head of Corporate Development | Sell | 1,583 | $201.18 | $318.5K | 0 |
| Feb 6, 2026 | Kramer Robin | Chief Financial Officer | Sell | 1,543 | $201.18 | $310.4K | 0 |
| Feb 6, 2026 | Murphy Nicole | Head of Pharm Ops and Tech | Sell | 3,339 | $201.18 | $671.7K | 0 |
| Feb 6, 2026 | Singhal Priya | Head of Development | Sell | 5,128 | $200.48 | $1.03M | 0 |
| Feb 6, 2026 | Viehbacher Christopher | President and CEO | Sell | 10,980 | $201.18 | $2.21M | 0 |
| Feb 3, 2026 | Singhal Priya | Head of Development | Sell | 1,330 | $179.56 | $238.8K | 0 |
| Dec 3, 2025 | Viehbacher Christopher | President and CEO | Sell | 3,404 | $177.78 | $605.2K | 0 |
| Nov 4, 2025 | Grogan Jane | Head of Research | Sell | 337 | $154.27 | $52.0K | 0 |
| Oct 6, 2025 | Godbout Sean | Chief Accounting Officer | Sell | 8 | $155.25 | $1.2K | 0 |
| Sep 2, 2025 | Singhal Priya | Head of Development | Sell | 1,324 | $132.74 | $175.7K | 0 |
| Jul 16, 2025 | Izzar Rachid | Head of Global Product Strat. | Sell | 2,223 | $135.00 | $300.1K | 0 |
| May 20, 2025 | Singhal Priya | Head of Development | Sell | 3,806 | $126.25 | $480.5K | 0 |
| May 5, 2025 | Keeney Adam | Head of Corporate Development | Sell | 454 | $120.93 | $54.9K | 0 |
| Mar 10, 2025 | SHERWIN STEPHEN A | Director | Sell | 8,760 | $150.02 | $1.31M | 0 |
| Feb 12, 2025 | ALEXANDER SUSAN H | EVP Chief Legal Officer | Sell | 807 | $142.54 | $115.0K | 0 |
| Feb 12, 2025 | Gregory Ginger | EVP, Human Resources | Sell | 634 | $142.54 | $90.4K | 0 |
| Feb 12, 2025 | Izzar Rachid | Head of Global Product Strat. | Sell | 445 | $142.54 | $63.4K | 0 |
| Feb 12, 2025 | Kramer Robin | Chief Accounting Officer | Sell | 245 | $142.54 | $34.9K | 0 |
| Feb 12, 2025 | MCDONNELL MICHAEL R | EVP, Chief Financial Officer | Sell | 1,371 | $142.54 | $195.4K | 0 |
| Feb 12, 2025 | Murphy Nicole | Head of Pharm Ops and Tech | Sell | 670 | $142.54 | $95.5K | 0 |
| Feb 12, 2025 | Singhal Priya | Head of Development | Sell | 357 | $142.54 | $50.9K | 0 |
| Feb 11, 2025 | Izzar Rachid | Head of Global Product Strat. | Sell | 1,165 | $141.35 | $164.7K | 0 |
| Feb 10, 2025 | ALEXANDER SUSAN H | EVP Chief Legal Officer | Sell | 1,234 | $141.35 | $174.4K | 0 |
| Feb 10, 2025 | Gregory Ginger | EVP, Human Resources | Sell | 1,040 | $141.35 | $147.0K | 0 |
| Feb 10, 2025 | Grogan Jane | Head of Research | Sell | 443 | $141.35 | $62.6K | 0 |
| Feb 10, 2025 | Keeney Adam | Head of Corporate Development | Sell | 563 | $141.35 | $79.6K | 0 |
| Feb 10, 2025 | Kramer Robin | Chief Accounting Officer | Sell | 476 | $141.35 | $67.3K | 0 |
| Feb 10, 2025 | MCDONNELL MICHAEL R | EVP, Chief Financial Officer | Sell | 1,502 | $141.35 | $212.3K | 0 |
| Feb 10, 2025 | Murphy Nicole | Head of Pharm Ops and Tech | Sell | 1,223 | $141.35 | $172.9K | 0 |
| Feb 10, 2025 | Singhal Priya | Head of Development | Sell | 681 | $141.35 | $96.3K | 0 |
| Feb 10, 2025 | Viehbacher Christopher | President and CEO | Sell | 3,201 | $141.35 | $452.5K | 0 |
| Jan 31, 2025 | Singhal Priya | Head of Development | Sell | 578 | $143.93 | $83.2K | 0 |
| Dec 6, 2024 | Kramer Robin | Chief Accounting Officer | Sell | 170 | $157.78 | $26.8K | 0 |
| Dec 6, 2024 | Singhal Priya | Head of Development | Sell | 316 | $157.58 | $49.8K | 0 |
| Nov 1, 2024 | Grogan Jane | Head of Research | Sell | 204 | $173.79 | $35.5K | 0 |
| Aug 30, 2024 | Singhal Priya | Head of Development | Sell | 1,238 | $204.57 | $253.3K | 0 |
| May 1, 2024 | Keeney Adam | Head of Corporate Development | Sell | 276 | $216.13 | $59.7K | 0 |
| Apr 2, 2024 | Singhal Priya | Head of Development | Sell | 93 | $213.09 | $19.8K | 0 |
| Apr 1, 2024 | Murphy Nicole | Head of Pharm Ops and Tech | Sell | 117 | $214.83 | $25.1K | 0 |
| Feb 22, 2024 | Singhal Priya | Head of Development | Sell | 262 | $221.23 | $58.0K | 0 |
| Feb 16, 2024 | ALEXANDER SUSAN H | EVP Chief Legal Officer | Sell | 2,437 | $219.08 | $533.9K | 0 |
| Feb 16, 2024 | Gregory Ginger | EVP, Human Resources | Sell | 2,264 | $219.08 | $496.0K | 0 |
BIIB Insiders
Similar Stocks to BIIB
LLY
Eli Lilly and Company
$874.10+0.67%
$869.14B
JNJ
Johnson & Johnson
$227.41+0.92%
$555.94B
ABBV
AbbVie Inc.
$197.12-0.13%
$360.31B
MRK
Merck & Co., Inc.
$109.93-0.26%
$289.58B
AMGN
Amgen Inc.
$338.53-0.49%
$188.76B
GILD
Gilead Sciences, Inc.
$128.97+0.94%
$168.65B
PFE
Pfizer Inc.
$26.39-1.49%
$156.54B
BMY
Bristol-Myers Squibb Company
$58.23+0.79%
$120.73B